Janni, Wolfgang http://orcid.org/0000-0001-5911-2400
Alba, Emilio
Bachelot, Thomas
Diab, Sami
Gil-Gil, Miguel
Beck, Thaddeus J.
Ryvo, Larisa
Lopez, Rafael
Tsai, Michaela
Esteva, Francisco J.
Auñón, Pilar Zamora
Kral, Zdenek
Ward, Patrick
Richards, Paul
Pluard, Timothy J.
Sutradhar, Santosh
Miller, Michelle
Campone, Mario
Clinical trials referenced in this document:
Documents that mention this clinical trial
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
https://doi.org/10.1007/s10549-017-4658-x
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials
https://doi.org/10.1007/s40262-022-01206-2
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 22 December 2017
Accepted: 30 December 2017
First Online: 5 February 2018
Compliance with ethical standards
:
: Dr. Janni reports grants and personal fees from Novartis during the conduct of the study and outside the submitted work. Dr. Alba reports advisory board fees from Roche, Pfizer, and Novartis outside the submitted work. Dr. Bachelot reports personal fees from AstraZeneca, Roche, Novartis, and Pfizer; research grants from Roche, Novartis, and Pfizer outside the submitted work. Dr. Esteva reports consulting fee and research funding to his institution. Dr. Pluard reports advisory board fees from Novartis. Mr. Sutradhar is an employee of Novartis Pharmaceutical Corporation. Dr. Miller is employee of Novartis Pharmaceutical Corporation and hold Novartis stock options. Prof. Campone reports fees for advisory boards from Novartis, during the conduct of the study; and fees for advisory boards from Lilly, Sanofi, Pfizer, and AstraZeneca outside the submitted work. Dr. Diab, Dr. Gil, Dr. Beck, Ryvo, Dr. Tsai, Dr. Aunon, Dr. Kral, Dr. Ward, and Dr. Richards have nothing to disclose.